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Objective: To investigate recent trends in the diagnosis and treatment of atrial ﬁbrillation.
Methods: Time trend analysis in the UK Clinical Practice Research Datalink (CPRD —previously the GPRD),
2000–2012.
Results: The incidence of AF inmen rose from1.274 (1.271, 1.276) per 1 000 patient years in 2000 to 1.972 (1.969,
1.975) in 2012. In women, it rose from 1.209 (1.207, 1.211) to 1.609 (1.606, 1.611).
55 847 patients with AF ﬁrst diagnosed between 2000 and 2012 were included in the study. 54% of men were
initiated on anticoagulation therapy in the ﬁrst year following diagnosis of atrial ﬁbrillation, compared to 45%
of women (P b 0.0001). This increased from 48% in men and 40% in women in 2000 to 58% in men and 52% in
women in 2012.
Conclusions: Identiﬁcation of atrial ﬁbrillation has improved in recent years, as has treatment for stroke preven-
tion. Although there has historically been a bias towardsmen in the treatment of stroke prevention in atrial ﬁbril-
lation, this study shows that the gap has been closing in recent years. Despite this improvement, this study shows
that there are still many patients with atrial ﬁbrillation who are not treated optimally to prevent stroke.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Atrial ﬁbrillation has been associated with a four to ﬁvefold increase
in the risk of stroke, and it has been estimated that 15% of all strokes are
caused by atrial ﬁbrillation [1]. The Echocardiographic Heart of England
Screening study reported a prevalence of atrialﬁbrillation of 2%, increas-
ing from 0.2% in people aged 45–54 to 8% in people aged 75 and older
[2]. A UK study published in 2002 reported an incidence of AF of 1.7
per 1000 person years in the General Practice Research Database [3]
(GPRD) in patients aged 40–89 in 1996.
However there has been evidence to suggest that atrial ﬁbrillation
often goes undiagnosed. Fitzmaurice et al. showed that in 50 primary
care centres in the UK, diagnosis of atrial ﬁbrillation increased by 60%
when screening was introduced compared to routine clinical practice
[4].
Anticoagulant and antiplatelet medication are licensed to treat pa-
tients with atrial ﬁbrillation to reduce the risk of stroke. In 2006 NICE.
land Ltd. Open access under CC BY-NCpublished guidelines [5] on the treatment of atrial ﬁbrillation, which
set out an algorithm for stratifying atrial ﬁbrillation patients by low,
moderate and high risk of stroke. The guidelines state that patients at
high risk of stroke should be treated with anticoagulation therapy,
and those at moderate risk of stroke should be treated with either
anticoagulation or antiplatelet therapy.
The BAFTA [6] study published in 2007 showed that treatingpatients
with anticoagulants such as warfarin is highly effective at reducing the
risk of stroke in patientswith atrialﬁbrillation,more so than antiplatelet
treatment such as aspirin. The European Guidelines published in 2012
state that aspirin should not be considered as an alternative to
anticoagulation therapy for stroke prevention in patients with atrial
ﬁbrillation [7].
However Gallagher et al. found in 2008 that a high stroke risk was
not associated with the initiation of warfarin or aspirin treatment, con-
trary to current guideline recommendations [8]. Recently Cowan et al.
found that between 2009 and 2012 over one third of patients who
should have been treatedwith anticoagulation therapywere not receiv-
ing it [9].
Treatment differences between men and women with coronary
heart disease have long been the subject of research. Despite the fact
that heart disease is the leading cause of death amongst women in the
UK [10] there has been evidence historically that womenwith coronary
disease are treated less aggressively than men [11,12], and that there is-ND license. 
Fig. 1. Incidence of atrial ﬁbrillation by sex and age.
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heart disease [13].
This evidence of treatment differences between men and women
extends to patientswith diagnosed atrialﬁbrillation. In 2001 a Canadian
study found that anticoagulants were underused in older women with
AF relative to older men despite comparable risk proﬁles [14]. De
Wilde et al. reported that in the UK between 1994 and 2003 treatment
of atrial ﬁbrillation with oral anticoagulants more than doubled in men
(25% to 53%) and rose in women also but to a lesser extent (21% to 40%)
[15].
In 2006 atrial ﬁbrillation was added to the Quality Outcomes Frame-
work (QOF) in England, which rewards and incentivises good practice
in the way GP surgeries identify and manage patients [16]. In 2008 the
GRASP-AF tool was made available nationally [17], an audit tool to
help GPs identify suitable patients for anticoagulation treatment,
which over 2200 practices are now using [18]. In this study, it was of
interest to examine recent trends in atrial ﬁbrillation diagnosis and
treatment, to discoverwhether these initiatives and guidelines have im-
proved clinical practice.
2. Methods
2.1. Data source
The CPRD (previously the GPRD) is a database of longitudinal patient primary care
records, containing anonymised data on patient demographics, diagnoses, referrals, pre-
scribing and health outcomes from over 660 GP practices in the UK. At February 2013
when the data for this study were extracted, there were 12.6 million patients of ‘accept-
able’ standard in the CPRD. Validation studies have conﬁrmed the high data quality and
completeness of clinical records within the CPRD [19–22].
2.2. Population
We included patients in the study if they were registered with a practice at any point
between 2000 and 2012 thatmet the CPRD “acceptable” standard for data quality. Patients
had to have been permanently registeredwith a CPRDpractice for at least 12 months prior
to their entry to the study, and have at least 12 months follow-up. This was to ensure that
every patient had at least 12 months of medical record prior to diagnosis of atrial ﬁbrilla-
tion, and 12 months of follow-up data in which to investigate comorbidities and pre-
scribed therapies.
We identiﬁed all patients aged 18 and over who had a ﬁrst diagnosis of non-valvular
atrial ﬁbrillation between 1 January 2000 and 31 December 2011. The Read codes used by
GPs to enter atrial ﬁbrillation into a patient record are shown in Appendix A.
2.3. Analysis
Data were extracted using the online version of CPRD, and analysed using SAS® Soft-
ware version 9.02. Incidence of atrial ﬁbrillation was calculated based on our cohort and
the total study population extracted from CPRD. We analysed the trend in incidence be-
tween 2000 and 2012 by sex and age.
Baseline characteristics of the cohort were summarised by sex and age group (18–64,
65–74, 75–84, 85+), including co-morbidities at the time of atrial ﬁbrillation diagnosis.
Stroke prophylaxis therapies prescribed in the year following diagnosis were summarised
(British National Formulary Sections 2.8 [anticoagulants], 2.9 [antiplatelet drugs]). We
have assumed that patients were treated with a medication if they received at least two
prescriptions for that medication in the year following diagnosis of atrial ﬁbrillation.
Stroke riskwas calculated using the algorithm in theNICE guidance [5]. This combines
patient agewith risk factors including hypertension, diabetes, vascular disease, stroke, TIA,
valve disease, heart failure, and impaired left ventricular function.
2.4. Follow-up
Patient datawere available from the time of ﬁrst diagnosis of atrial ﬁbrillation until 31
December 2012 or when the patient transferred out of the practice or died. We examined
trends in the proportion of patients treated with anticoagulation and antiplatelet therapy
in the year following a diagnosis of atrial ﬁbrillation.
3. Results
3.1. Incidence of atrial ﬁbrillation
Fig. 1 shows how the incidence of diagnosed atrial ﬁbrillation in
CPRD has risen over the duration of the study period in both men and
women (Cochran–Armitage test for trend: P b 0.0001). This increaseis most marked in patients aged over 65, and in the years from 2009 on-
wards. In men the incidence went from 1.274 (95% conﬁdence interval
(1.271, 1.276)) per 1000 patient years in 2000 to 1.972 (1.969, 1.975) in
2012. Inwomen it rose from 1.209 (1.207, 1.211) per 1000 patient years
to 1.609 (1.606, 1.611) over the same period.
3.2. Atrial ﬁbrillation cohort
Therewere 55 847patients (29 361men (53%) and 26 486women)
in CPRDwho had a ﬁrst diagnosis of atrial ﬁbrillation between 2000 and
2011 and met our inclusion criteria. The mean age in men was 70.7
(standard deviation 12.0) and 76.3 (10.6) in women.
3.3. Treatment trends—Initiation of treatment in year following diagnosis
of atrial ﬁbrillation
54% ofmenwere initiated on anticoagulation therapy in the ﬁrst year
following diagnosis of atrial ﬁbrillation, compared to 45% of women
(P b 0.0001). The proportion of patient treated with anticoagulation
therapy was highest in patients aged 65–74 (62% in men, 56% in
women) and lowest in patients aged 80 and above (34% in men, 27% in
women). 49% of men received antiplatelet therapy compared to 53% of
women (P b 0.0001).
Fig. 2 shows the trend over time in the proportion of men and
women treated with anticoagulant and antiplatelet therapy in the ﬁrst
year following diagnosis of atrial ﬁbrillation. The percentage of patients
prescribed neither anticoagulant nor antiplatelet therapy has been de-
creasing year on year since 2000. The proportion of patients prescribed
anticoagulant therapy has increased in both men and women, and the
gap between the sexes has decreased year on year, from 48% in men
and 40% in women in 2000 to 58% in men and 52% in women in 2012.
The proportion of patients prescribed both anticoagulant and antiplate-
let therapy in the year following diagnosis has increased, while the
Fig. 2. Percentage of patients prescribed stroke prevention therapies in year following atrial ﬁbrillation diagnosis.
171A.C.E. Scowcroft, M.R. Cowie / International Journal of Cardiology 171 (2014) 169–173proportion of patients prescribed antiplatelet therapy only rose slightly
up until 2009 after which it has been decreasing.
3.4. Treatment by stroke risk
Fig. 3 shows the proportion of patients treated with anticoagulation
and antiplatelet therapy in the ﬁrst year following atrial ﬁbrillation
diagnosis, by risk of stroke. This shows that in both men and women
the proportion of patients treated with anticoagulation therapy in the
ﬁrst year following atrial ﬁbrillation diagnosis has increased since
2000, and the proportion of patients not treated for stroke prevention
has decreased. These increases are more evident in patients regarded
as high or moderate risk of stroke using the NICE algorithm [14] than
in patients at low risk.
4. Conclusions
4.1. Main results
This study found an increase in the rate of diagnosis of atrial ﬁbrilla-
tion since 2000, with a sharper incline starting in 2009. This is in
contrast to studies recently published on US patients which showed a
constant rate of atrial ﬁbrillation diagnosis from 1993 to 2007 [23],
and even a decline in the rate of atrial ﬁbrillation diagnosed at hospital
discharge between 2005 and 2009 [24].
It is likely that this difference in trend is caused by an increase in the
identiﬁcation of atrial ﬁbrillation in the UK in recent years. It has been
reported that atrial ﬁbrillation is a condition which has frequently
been under diagnosed [4]. Recent initiatives in the UK to tackle this in-
clude the NICE guidance published in 2006 [5] and the GRASP-AFinitiative [18]. Our results suggest that these initiatives may be begin-
ning to produce results.
Studies in theUKhave shown under-treatment of patients for stroke
prevention in atrial ﬁbrillation [8,9]. The addition of atrial ﬁbrillation to
the QoF in 2006 incentivised GPs in England to treat patients with
anticoagulation or antiplatelet therapy. This study, which analyses
treatment by year over a 12 year period, shows that although there
are still patients who should be receiving anticoagulation therapy who
are not, the proportion of patientswho do receive it has been increasing.
The recent change to the QoF measures for atrial ﬁbrillation in 2012
which encourages GPs to treat patients at a high risk of stroke with
anticoagulation therapy should address this further [25].
The evidence of an increase in the proportion of patients treated
with anticoagulant therapy in patients at high ormoderate risk of stroke
which is not seen in patients at low risk of stroke suggests that the risk
stratiﬁcation of patients has also been improving. Not only are more
patients being treated for stroke prevention, but also these additional
patients are the patients who should be receiving it. However there is
evidence that the rate of prescribing of antiplatelet therapy has in-
creased over the study period too, and there are also a group of patients
who are still not treated for stroke prevention, which suggests that
there are still patients who are not being treated optimally.
Despite some suggestion that women with atrial ﬁbrillation are at
higher risk of stroke than men [9] NICE concludes that as there is no
biological plausibility for a difference in stroke risk between the sexes,
female patients should not be considered at greater risk than men
[10]. This suggests that for any given set of comorbidities, comedications
and stroke risk factors, female patients should have an equal likelihood
of being anticoagulated to that ofmale patients. However, past evidence
highlights that this is not the case [17].
Fig. 3. Percentage of patients prescribed stroke prevention therapies in year following atrial ﬁbrillation diagnosis by stroke risk.
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tween 2000 and 2012 the gender gap in treatment with anticoagulation
in patients with atrial ﬁbrillation has been closing, to a point where the
difference is minimal.
4.2. Limitations
The CPRD contains prescription data for therapies prescribed in pri-
mary care, but it does not include any prescribed in secondary care.
Therefore we may fail to identify where patients have been treated if
they were prescribed the medication only in secondary care. This issue
should be minimal, because even if patients are initiated on stroke pre-
vention treatment in secondary care, the prescriptionwill almost exclu-
sively be continued on this therapy in primary care, so we would
identify this.
5. Conclusions
This study shows evidence that identiﬁcation of atrial ﬁbrillation has
increased between 2000 and 2012, probably due to improved aware-
ness of the condition. NICE guidance and theGRASP-AF initiative appear
to have had an effect, driving improvements in treating patients for
stroke prevention. The gender bias in stroke prevention treatment
seen in previous studies, with men being more likely to be treated
than women, still exists but the gap has been closing in recent years.
The proportion of patients treated with anticoagulation therapy has in-
creased, but there are still patients with atrial ﬁbrillation who are not
treated optimally to prevent stroke.Contributors
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